SALT LAKE CITY, Oct. 18, 2018 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTC/PINK: PRED), a leader in the use of data analytics for disease identification and subsequent therapeutic intervention through precision therapeutic treatments, announces the appointment of Charles Andres, J.D., Ph.D., RAC, HBX CORe, to its Scientific Advisory Board.
As an attorney at Wilson Sonsini Goodrich & Rosati (WSGR), Mr. Andres leads the life sciences group in that firm’s Washington DC office. He represents a broad range of companies, including those at the forefront of cellular therapy, regenerative medicine, diagnostics, and immuno-oncology. His practice encompasses intellectual property, FDA/regulatory, transactional, business, and governmental matters. Prior to becoming a patent professional, Mr. Andres spent a decade as a medicinal chemist and early-phase project co-chair at Bristol-Myers Squibb Company, where he won a Presidential Award among other accolades. He holds Regulatory Affairs Certification (RAC) from the Regulatory Affairs Professionals Society.
“We are very pleased to have Charlie join our Scientific Advisory Board,” said Bradley Robinson, CEO of Predictive Technology Group. “In additional to advising Predictive on IP matters, Charlie has made significant contributions to Predictive in its strategic and business development activities and transactions. Having Charlie sit as a member of the Predictive Scientific Advisory Board will be of great strategic benefit to our Company.”
“I am excited to join the Scientific Advisory Board of Predictive and to work with the Company’s cutting-edge technologies to improve the lives of patients suffering from chronic diseases,” said Mr. Andres. “I look forward to helping Predictive fulfill its mission of changing patients’ lives through novel disease diagnostics and subsequent therapeutic intervention by leveraging its unique and proprietary development platforms.”
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its wholly owned subsidiaries Predictive Therapeutics and Predictive Biotech. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com; Predrx.com and Predictivebiotech.com.
Forward-Looking Statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.
Contact:
Investors
LHA Investor Relations
Jody Cain jcain@lhai.com
Kevin Mc Cabe kmccabe@lhai.com
310-691-7100